| 1 | |
|----------------|--|
| 2 | |
| 3 | Variant rs9644568 in the intergenic region downstream of the LPL gene is associated with |
| 4 | high LDL cholesterol levels among Filipinos |
| 5 | |
| 6 | |
| 7 | Eva Maria C. Cutiongco–de la Paz ^{1,2*¶} , Jose B. Nevado, Jr. ^{1¶} , Lourdes Ella G. Santos ^{3¶} , |
| 8 | Aimee Yvonne Criselle L. Aman ^{1,2¶} , Jose Donato A. Magno ^{3¶} , Paul Ferdinand M. |
| 9 | Reganit ^{3¶} , Richard Henry P. Tiongco II ^{3¶} , Deborah Ignacia D. Ona ^{3¶} , Felix Eduardo R. |
| 10 | Punzalan ³ ¶, Elmer Jasper B. Llanes ³ ¶. Jaime Alfonso M. Aherrera ³ ¶, Carla Mae O. |
| 11 | Fernandez ¹ ¶, Lauro L. Abrahan IV ³ ¶, Charlene F. Agustin ³ ¶, Adrian John P. Bejarin ^{1,2} ¶, and |
| 12 | Rody G. Sy ³ ¶ |
| 13 | |
| 14 | |
| 15 | ¹ Institute of Human Genetics, National Institutes of Health, University of the Philippines Manila, Philippines |
| 16 | ² Philippine Genome Center, University of the Philippines Diliman, Quezon City, Philippines |
| 17 | ³ Department of Medicine, Philippine General Hospital, University of the Philippines Manila, Philippines |
| 18 19 20 | *corresponding author |
| 21 | E-mail: eccutiongcodelapaz@up.edu.ph |
| 22 | |
| 23 | ¶These authors contributed equally to this work |
| 24 | |

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

26

27 High blood level of low-density lipoprotein cholesterol (LDL-C) is a major risk factor for 28 cardiovascular disease. Although genetic variants linked to high LDL-C have been studied in other 29 populations, there have been no previous studies among Filipinos. This study aims to determine 30 the association of candidate genetic variants to high LDL-C. We performed an age- and sex-31 matched case-control study that compared Filipino participants with high LDL-C levels (n=60) 32 with controls (n=60). DNA was extracted from blood samples and genotyped for candidate SNPs 33 using a customized microarray chip. Logistic regression analyses were used to determine the 34 composite association of genetic and clinical variables to the condition. Of the initial eleven SNPs 35 associated with high LDL-C in univariate analyses, only the variant rs9644568 in the intergenic 36 region downstream of the LPL gene remained significantly associated with high LDL-C levels 37 on multiple regression analysis and variable selection after adjustment for hypertension. The G 38 allele was observed as the risk allele in a recessive model. The variant rs9644568-G in the LPL 39 gene was associated with high blood LDL-C levels among Filipinos. In combination with 40 hypertension, this genetic profile may identify individuals who are susceptible to develop high 41 LDL-C in this population.

42

43 * Corresponding author

44 E-mail: eccutiongcodelapaz@up.edu.ph

3

Introduction 45

46

47 Low-density lipoprotein cholesterol (LDL-C) level is a risk factor and a traditional target for preventive cardiovascular disease (CVD) interventions. This association is enhanced in the presence 48 49 of atherosclerosis [1], and the common view is that it is an active component of atherogenesis [2]. 50 Several studies have since reported reduced adverse cardiovascular events after treatment with LDL-51 C-lowering drugs [2-4].

52 LDL-C levels may be affected by several factors, including genetics. A common familial form 53 of LDL-C elevation, familial hypercholesterolemia (FH), has been well studied and three causative 54 genes have already been identified, namely low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9). In addition, several studies on 55 56 hereditary dyslipidemias have shown a variety of genes involved, such as low density lipoprotein receptor adaptor protein 1 (LDLRAP1), ATP binding cassette subfamily G members 5 and 8 57 58 (ABCG5, ABCG8), angiopoietin like 3 (ANGPTL3), microsomal triglyceride transfer protein 59 (MTTP), myosin regulatory light chain interacting protein (MYLIP), apolipoproteins A5, B, C2 and E (APOA5, APOB, APOC2, APOE), and lipoprotein lipase (LPL), which as expected, are involved in 60 61 lipid metabolism, transport and processing [5,6].

62 Genotyping efforts in recent years attempted to find possible genetic susceptibility loci. For 63 instance, genome-wide association studies (GWAS) have implicated LDLR, APOE, and 3-hydroxy-3-64 *methylglutaryl-coenzyme A reductase (HMGCR)* as possible key regulators of lipid metabolism to 65 high LDL-C [7-9]. Other genes that were considered include fatty acid desaturase 1 (FADS1), 66 polypeptide N- acetylgalactosaminyltransferase 2 (GALNT2), and acetyl-coenzyme A carboxylase 67 *beta* (*ACACB*) [10-12].

68 However, findings from studies of genetic polymorphisms cannot be generalized across 69 populations due to inherent inter-ethnic differences in genetic profiles. To illustrate, among the 70 Taiwanese population, a PCSK9 variant has been determined to have a causally significant 71 association with high LDL-C levels; however, this association is not found among the Italian 72 population [13,14]. In another study, a novel polymorphism of the ICAMI was reported to be

4

associated with LDL-C in African Americans at conventional genome-wide significance, but not among Hispanics and East Asians [15]. Such discrepancies warrant verifying associations between genotypes and LDL-C levels in newly investigated populations. This could be due to independently evolved genetic differences with similar phenotypes due to metabolic proximity. Data from different ethnic populations will be able to contribute to a better understanding of diseases and can enhance customized clinical applications for individual populations.

Due to scarce data on genetic associations with LDL-C among Filipinos, this study aimed to identify candidate genetic markers associated with high LDL-C levels in this population. In addition to direct association, the variants were interpreted in the context of traditional risk factors to account for their significant, but potentially interdependent influences.

- 83 Methodology
- 84 85

86

Study design and ethics clearance

This is an age- and sex-matched case-control study performed from July 9, 2013 to March 31, 2017. This study complied to the Principles of the Declaration of Helsinki (2013) and all experimental protocols in this study were approved by the University of the Philippines Manila-Research Ethics Board (Study protocol code UPMREB- 2012-0186-NIH). The investigators confirm that the methods complied with the relevant guidelines and regulations of UPMREB.

92 93

Enrollment of participants and clinical data collection

94 Participants were enrolled from the Philippine General Hospital, different local communities, 95 and clinics in Metro Manila. They were unrelated, aged 18 years old and above, of Filipino descent 96 up to the 3rd degree of consanguinity, and could provide independent consent. Cases were defined as 97 (a) having at least one reading of serum LDL-C ≥ 160 mg/dl as defined by the NCEP ATP III 98 guidelines; and (b) had not ever been on antilipidemics. Controls were participants with (a) at least 99 one reading of serum LDL-C <160 mg/dl; and (b) without a previous diagnosis of dyslipidemia. 100 Participants were excluded if they had end-stage renal disease, decompensated chronic liver disease, 101 active malignancy, chronic lung disease, secondary hypertension, secondary dyslipidemia, or if 102 pregnant. The demographic data and clinical characteristics were obtained from patient records and

5

verbal interviews. Clinical data, including lipid profile and serum creatinine, were also recorded.
Written informed consent forms duly approved by the UPMREB was obtained from potential
participants prior to recruitment to the study.

106 107

DNA extraction and quantification

DNA was extracted using the QiaAmp DNA Mini Kit following the spin protocol for blood buffy coat as specified in the manufacturer's instruction manual. DNA was quantified using a spectrometer at 260nm and stored at -20°C until use. All DNA samples had A-260nm/A-280nm values above 1.80.

112 113

2 Customized genotyping

114 A customized GoldenGate Genotyping (GGGT) beadchip (Illumina, Inc., San Diego, CA, 115 USA) was designed in 2012 using candidate SNPs from both coding and noncoding regions, 116 including intergenic and intronic SNPs, which have shown evidence of association with high LDL-117 C levels and lipid metabolism. These were selected after an extensive search in the following databases: 118 Pharmacogenomics Knowledgebase database (PharmGKB), National Human Genome Research 119 Institute Genome-Wide Association Study Catalog (NHGRI GWAS Catalog), PubMed, and selected 120 international patent databases (e.g., Patentscope and Espacenet). The selected SNPs were submitted to Illumina, Inc. for scoring to determine the suitability of the SNPs to discriminate for microarray 121 assay and to estimate their specificity. 122

Customized genotyping of candidate SNPs was performed using DNA microarray technology following the GoldenGate Genotyping (GGGT) protocol specified in the manufacturer's manual. While the microarray platform is optimally designed to detect bi-allelic SNPs, the study included tri- or quad-allelic SNPs using the reference allele and the most common alternative in cases where the variants correlate with significant clinical outcomes. After microarray processing, the beadchip was imaged on the HiScan System, and data from these images were analyzed using GenomeStudio software.

- 130
- 131

6

132 Data analysis

133

135

141

143

134 **Quality control**

GenomeStudio 2.0 and PLINK version 2.05.10 were used for data cleanup using the following criteria: call rates \geq 95%, minor allele frequency (MAF) of \geq 0.01, genotype missingness of \leq 0.05, individual missingness \leq 0.05, and not having a Hardy-Weinberg equilibrium (HWE) of p < 0.001 in the control group.

142 **Statistical analysis**

144 Chi-squared test and Fisher exact test, as applicable, were used for categorical data, and the 145 student *t-test* was used for quantitative data were performed to assess for significant differences 146 between alleles and genotypes (i.e., allelic and genotypic association tests, which include additive, 147 dominant and recessive models). These models were identified based on the distribution of the case 148 and control genotypes. Tests for allelic and genotypic associations were done by setting the cut-off 149 at Bonferroni-corrected p < 0.05.

Upon determination of genotypic effects, the genotypes were recorded according to the most significant model, with imputations made for missing data. Univariate analysis was done to determine the association of SNPs with high LDL-C phenotype. A multiple logistic regression using stepwise backward elimination was performed with nominal $p \le 0.05$ and clinical variable with $p \le 0.20$.

154 **Results**

155

After data quality control, the final set of samples for analysis included 120 participants consisting of 60 cases and 60 controls (Fig 1A). Using age- and sex-matched case-control design, the 120 participants were genotyped using 132 genomic variants.

159 Of the 132 variants selected for the study, 50 variants were removed after quality control 160 with PLINK: 33 SNPs failed the Hardy-Weinberg test (p > 0.001) among controls, ten SNPs had 161 missing genotype data for more than 5% of the individuals, and one SNP was removed because the 162 minor allele frequency was lower than 1% (Fig 1B). Eleven variants were significantly associated 163 with high LDL-C after adjusting for multiple testing (i.e., Bonferroni-adjusted $\alpha = 0.05$).

164

7




FIG 1. Schematic diagram of data processing and analysis for the high LDL-C group. A total
 of 183 participants (A) and 132 SNPs (B) were analyzed to determine the association of genetic
 variants with high LDL-C and lipid metabolism. Abbreviations: MIND – individual missingness;
 SNP – single nucleotide polymorphism; HWE – Hardy-Weinberg equilibrium; GENO – genotypic
 missingness

Table 1 summarizes the clinical characteristics of the included participants. Their crude odds ratios are in Table S1. Participants in the high LDL-C group tend to have more comorbidities that showed significance such as hypertension (p < 0.0001), BMI ≥ 25 kg/m² (p = 0.056), and ischemic heart disease (p = 0.002). The cases also seemed to have slightly elevated creatinine levels.

177

165 166

| TABLE 1 Clinic | al characteristics (| of narticinant | s included in the stu | dv |
|----------------|------------------------|-----------------|-----------------------|----|
| TADLE I. CHIR | al chai acter istics (|) i pai ucipani | s menuucu m the stu | uy |

| Characteristics | Participants with high LDL-C (n = 60) | Participants with normal LDL-C (n = 60) | <i>p</i> -value* | |
|--------------------------------|---|---|------------------|--|
| Age ≥ 60 years, % | 40.00 | 40.00 | 1.000 | |
| Sex, % male | 38.33 | 38.33 | 1.000 | |
| Co-morbidities, % | | | | |
| Hypertension | 86.67 | 28.33 | < 0.001 | |
| BMI ≥ 25 kg/m ² | 43.33 | 26.67 | 0.056 | |
| Diabetes mellitus | 20.00 | 0.00 | > 0.999 | |
| Previous stroke | 1.67 | 1.67 | 1.000 | |
| Ischemic heart disease | 45.00 | 13.33 | 0.002 | |
| eGFR < 60 ml/min | 10.00 | 5.00 | 0.215 | |
| Lifestyle factors, % | | | | |
| Smoker (both current and past) | 28.33 | 25.00 | 0.638 | |
| Alcohol drinker (>2 | | | | |
| shots per day) | 50.00 | 46.67 | 0.618 | |
| Blood chemistry | | | | |
| Creatinine, mg/dl | 0.90 (0.42) | 0.80 (0.19) | 0.094 | |
| Total cholesterol, mg/dl | 273.79 (44.54) | 193.01 (25.66) | < 0.001 | |
| Triglycerides, mg/dl | 159.47 (68.76) | 91.70 (36.67) | < 0.001 | |
| HDL, mg/dl | 52.46 (14.19) | 56.94 (13.50) | 0.079 | |
| LDL, mg/dl | 191.88 (41.34) | 120.62 (21.87) | < 0.001 | |
| eGFR, ml/min | 87.72 (24.42) | 93.33 (18.77) | 0.161 | |

| | : SD – standard deviation; BMI – body mass index; eGFR – estimated glomerular filtration rate; HDL – poprotein; LDL – low-density lipoprotein |
|---------------|--|
| *Significance | set at $p < 0.05$ using Chi-squared test for age and sex, conditional logistic regression for comorbidities actors, and Student's <i>t</i> test for continuous variables |
| The | ere were 11 variants found to have a statistically significant association with LDL-C |
| levels on th | are genotypic association test after adjusting for multiple testing (Bonferroni-adjusted α |
| = 0.00061) | (Table S2). These variants underwent logistic regression analysis for the computation |
| of their OR | and to determine which will retain significance upon adjusting for other variables (Table |
| 2). One SN | IP had clinically significant odds ratios (OR ≥ 2.5) and was statistically significant (p |
| <.001) on s | imple logistic regression analysis: rs12279250 in NELL1. This SNP seemed to display |
| a dominant | genotypic effect. |
| | |
| Cli | nical variables with a significant difference between the two groups, $p \le 0.20$: |
| hypertensic | on, BMI ≥ 25 kg/m ² , and ischemic heart disease were included together with the 11 |
| variants wit | th nominal $p < 0.05$ in the full model for the multiple regression analysis (Table 3). On |
| variable sel | lection using the stepwise algorithm ($p < 0.05$), only the presence of hypertension and |
| | notained their aignificant appreciation with high IDL Clauses under an additive model |

| 187 188 | Clinical variables with a significant difference between the two groups, $p \le 0.20$: |
|------------|---|
| 189 190 | hypertension, $BMI \ge 25 \text{ kg/m}^2$, and ischemic heart disease were included together with the 11 |
| 190 191 | variants with nominal $p < 0.05$ in the full model for the multiple regression analysis (Table 3). On |
| 192 | variable selection using the stepwise algorithm ($p < 0.05$), only the presence of hypertension and |
| 193 | rs9644568 retained their significant association with high LDL-C levels under an additive model |
| 194 | with allele G as the risk allele (AG vs. GG: adjusted OR = 2.44, 95% CI = $0.41-20.60$; $p = 0.355$; |

| 194 | with allele G as the risk allele (AG vs. GG: adjusted OR = 2.44 , 95% CI = $0.41-20.60$; $p = 0.355$ |
|-----|---|
| | TABLE 2. Univariate logistic regression analysis of the significant variants |

| SNP | Chr | Implicated Gene | Variant Role | Risk Allele | Risk Allele Frequency | Genotype | Crude Odds Ratio (95% Cl) | <i>p</i> - value* |
|------------|-----|--------------------|---------------------------|-------------|--------------------------|----------------|------------------------------------|----------------------|
| rs9644568 | 8 | LPL | Intergenic (regulates | G | 0.60 | AG vs AA | 2.36 (0.50, 17.27) | 0.320 |
| | | | LPL as by GTex Portal) | | | GG vs AA | 13.00 (3.27, 87.36) | 0.001 |
| rs1045642 | 7 | ABCB1 | synonymous variant | A | 0.325 | AG vs AA | 2.43 (1.03, 5.94) | 0.046 |
| | | | | | | GG vs AA | 7.33 (2.58, 23.07) | <0.001 |
| rs12279250 | 11 | NELL1 | intron variant | G | 0.54 | GG vs AG/AA | 2.20 (1.01, 4.96) | 0.051 |
| rs1532085 | 15 | LIPC | unknown | A | 0.20 | AG vs GG | 2.44 (1.05, 5.80) | 0.039 |
| | | | | | | AA vs GG | 5.33 (1.88, 18.47) | 0.003 |

GG vs AA: adjusted OR = 10.66, 95% CI = 2.15-81.05; *p* = 0.008) (Table 4).

9

| | | | | | | AG vs AA | 2.86 (1.25, | 0.014 |
|-----------|---|----------|---------------------|------|----------|----------|----------------|-------|
| rs4149268 | 9 | ABCA1 | intron variant | G | 0.26 | | 6.73) | |
| | | | | | | | 4.72 | 0.004 |
| | | | | | | GG vs AA | (1.71, | |
| | | | | | | | 14.22) | |
| | | | | | | | 0.75 | 0.706 |
| | | | intron / | | o = o | AC vs CC | (0.17, | |
| rs4299376 | 2 | ABCG8 | upstream | С | 0.70 | | 3.56) | |
| | | | gene variant | | | ~~ ~ ~ | 3.41 | 0.056 |
| | | | 3 | | | CC vs AA | (1.02, | |
| | | | | | | | 13.43) | |
| | | | | | | | 2.95 | 0.019 |
| | | | | | | AG vs GG | (1.21, | |
| rs676210 | 2 | APOB | missense | A | 0.38 | | 7.47) | |
| | | | variant | | | | 4.31 | 0.003 |
| | | | | | | AA vs GG | (1.69, | |
| | | | | | | | 11.56) | |
| | | | | | | | 3.10 | 0.017 |
| | _ | 7 CYP3A5 | splice | 0 | 0.37 | AG vs AA | (1.26, | |
| rs776746 | 1 | | acceptor / | G | | | 8.15) | 0.004 |
| | | | intron / 5'- | | | ~~ ~ ~ | 6.79 | 0.001 |
| | | | UTR variant | | | GG vs AA | (2.38, | |
| | | | | | | | 21.20) | 0.000 |
| | | | | | | 10 | 4.35 | 0.002 |
| | | 0011144 | upstream | | A 0.35 | AG vs GG | (1.74, | |
| rs2686586 | 3 | 3 GOLIM4 | gene variant; | A | | | 11.66) | .0.00 |
| | | | intergenic | | | | 7.03 | <0.00 |
| | | | 0 | | | AA vs GG | (2.59, | |
| | | | | | | | 20.73) | 0 570 |
| | | | | | | | 0.71 | 0.578 |
| | 0 | | | 0 | 0.50 | GC vs GG | (0.20, | |
| rs7016880 | 8 | LPL | downstream | G | 0.56 | | 2.38) | 0.007 |
| | | | gene variant | | | ~~~~~ | 3.60 | 0.007 |
| | | | | | | CC vs GG | (1.44, | |
| | | | | | | | 9.54) | 0.010 |
| | | | | | | | 2.78 | 0.240 |
| | | 3'-UTR | 0 | 0.00 | AG vs AA | (0.58, | | |
| rs660240 | T | 1 CELSR2 | variant | G | G 0.68 | | 20.45) | 0.040 |
| | | | | | | | 7.58 | 0.012 |
| | | | | | | GG vs AA | (1.84, | |
| | | | nily B member 1 · A | | | | 51.54) | |

ABCB1 = ATP binding cassette subfamily B member 1; *ABCA1* = ATP binding cassette subfamily A member 1; *ABCG8* = ATP binding cassette subfamily G member 8; *APOB* = apolipoprotein B; *CELSR2* = cadherin EGF LAG seven-pass G-type receptor 2; CI = confidence interval; *CYP3A5* = cytochrome P450 family 3 subfamily A member 5; *GOLIM4* = golgi integral membrane protein 4; *INTS10* = integrator complex subunit 10; *LIPC* = lipase C; *LPL* = lipoprotein lipase; *NELL1* = neural EGFL like 1; *SLC18A1* = solute carrier family 18 member A1; SNP = single nucleotide polymorphism; *ZPR1* = zinc finger protein ZPR1;

*Significance set at p < 0.05 on conditional logistic regression analysis

196

TABLE 3. Genetic variants and clinical factors in the multiple regression full model.

| Factors | Genotype | Adjusted OR (95% CI) | <i>p</i> -value |
|----------------------------|-------------|-----------------------|-----------------|
| Hypertension | - | 28.02 (6.14, 183.90) | < 0.001 |
| BMI ≥ 25 kg/m ² | - | 3.73 (0.95, 16.69) | 0.068 |
| Ischemic heart | - | | 0.259 |
| disease | | 0.37 (0.06, 1.95) | 0.200 |
| rs9644568 | AG vs AA | 1.92 (0.17, 33.73) | 0.612 |
| | GG vs AA | 38.82 (2.08, 1758.82) | 0.030 |
| rs1045642 | AG vs AA | 4.96 (0.75, 40.90) | 0.111 |
| | GG vs AA | 18.82 (1.53, 358.85) | 0.032 |
| rs12279250 | AA vs AG/GG | 2.37 (0.35, 15.77) | 0.359 |
| rs1532085 | AG vs GG | 0.66 (0.07, 5.18) | 0.697 |
| | AA vs GG | 3.90 (0.46, 40.06) | 0.221 |
| rs4149268 | AG vs AA | 4.89 (1.00, 27.94) | 0.058 |
| | GG vs AA | 22.36 (2.73, 270.92) | 0.007 |
| rs4299376 | AG vs GG | 0.25 (0.01, 3.89) | 0.333 |
| | | | |

| 1 | Λ |
|---|---|
| I | υ |

| | AA vs GG | 0.08 (<0.01, 1.40) | 0.101 |
|-----------|----------|-----------------------|-------|
| rs676210 | AG vs GG | 1.22 (0.17, 8.13) | 0.838 |
| | AA vs GG | 0.82 (0.10, 6.54) | 0.848 |
| rs776746 | AG vs AA | 2.64 (0.41, 18.38) | 0.309 |
| | GG vs AA | 11.57 (1.18, 163.68) | 0.047 |
| rs2686586 | AG vs AA | 0.27 (0.03, 2.38) | 0.240 |
| | GG vs AA | 0.81 (0.08, 8.64) | 0.860 |
| rs7016880 | GC vs GG | 0.17 (0.01, 2.48) | 0.212 |
| | CC vs GG | 0.11 (0.01, 1.22) | 0.088 |
| rs660240 | AG vs AA | 44.94 (1.47, 6062.32) | 0.068 |
| | GG vs AA | 8.43 (0.44, 241.37) | 0.174 |

BMI = body mass index; CI = confidence interval; OR = odds ratio

197 198

TABLE 4. Genetic variants and clinical factors remaining after variable selection.

| Variable | Genotype | Adjusted OR (95% CI) | p-value |
|--------------|----------|----------------------|---------|
| rs9644568 | AG vs AA | 2.44 (0.41, 20.60) | 0.355 |
| | GG vs AA | 10.66 (2.15, 81.05) | 0.008 |
| Hypertension | - | 14.23 (5.53, 40.81) | < 0.001 |

199 *Significance set at p<0.05; Abbr: CI = confidence interval; OR = odds ratio

200

202

201 **Discussion**

Genetic determinants of high LDL-C may be helpful in the understanding and optimum management of cardiovascular risk. As associated variations often differ across populations, especially for complex conditions, studies on Filipinos must be undertaken considering that cardiovascular disease remains as the top cause of mortality in the country. This study analyzes candidate genetic variants of high LDL-C among Filipino patients. In addition, a regression model of candidate genetic variants incorporating traditional clinical risk factors was generated to assess their relative effects on LDL-C profiles.

Univariate analyses found 11 variants associated with LDL-C levels. The reported genes
include *lipoprotein lipase (LPL), ATP binding cassette subfamily B member (ABCB1), lipase C*(*LIPC*), *ATP binding cassette subfamily A member (ABCA1), ATP binding cassette subfamily G member 8 (ABCG8), apolipoprotein B (APOB),* and *cadherin EGF LAG seven-pass G-type receptor*2 (*CELSR2*). Expectedly, these are known genes whose roles in LDL-C metabolism are well
established — from lipid transport, cellular metabolism and homeostasis, cellular translocation, and
storage [16-21].

11

217 A major finding in this study is the variant rs9644568 near the LPL gene. Logistic 218 regression with adjustment for hypertension shows a significant association of rs9644568 to high 219 LDL-C levels after adjusting for hypertension among Filipinos. The G allele of rs9644568 confers 220 a 2.44-fold increased risk for high LDL-C in heterozygous individuals and a 10.66-fold increased 221 risk in homozygous individuals. This suggests a possible additive or a multiplicative model of 222 transmission. This is similar to the findings of a genome-wide association study among Europeans, 223 which consistently demonstrated the significant association of G allele of rs4977574 with high LDL-224 C levels and an increased risk of myocardial infarction (MI) [22]. In contrast, the minor G allele protects LDL-C in another study that included Hispanics, East Asians and also Europeans [23]. A 225 226 similar study found the minor G allele to be associated with decreased risk for coronary artery 227 disease and peripheral artery disease in a Chinese population with diabetes [24].

228 The SNP rs9644568 is located on chromosome 8p21.3 in an intergenic region downstream 229 of the gene LPL (UCSC Genome Browser, http://genome.ucsc.edu, Accessed October 10, 230 2023). Although the variant is >100 kb far from the gene LPL, expression from several tissues 231 suggests that it regulates the gene (GTEx Portal. https://gtexportal.org. Accessed October 10, 2023). 232 This gene is predominantly expressed in the heart, skeletal muscles, and adipose tissues²⁵. LPL 233 encodes a rate-limiting enzyme called lipoprotein lipase, which plays an important role in lipid metabolism, as well as in lipid intake and clearance. Lipoprotein lipase aids in the breakdown of 234 235 the circulating triglyceride-rich lipoproteins in the bloodstream and the uptake of free fatty acids 236 into peripheral organs for energy storage and consumption [26-30]. Alterations in LPL activity 237 could result in dyslipidemia, characterized by increased plasma LDL-C, TG, and reduced plasma 238 HDL-C levels [31]. This association of the variant is interesting, as prior data, to our knowledge, do 239 not indicate rs9644568 as a risk marker for high LDL levels or as having the highest odds ratio in 240 any non-Filipino population. This can imply that the variant is a unique risk marker for Filipinos, independent of other components of metabolic syndrome, i.e., hypertension and diabetes mellitus. 241

To support the significance of *LPL* as a candidate locus, the study also indicated that another downstream *LPL* variant, rs7016880, was associated with LDL-C. Interestingly, rs7016880 shares

12

many characteristics with rs9644568 – being located as a downstream non-coding regulator,
having a possible multiplicative model, with a high odds ratio. This may provide greater confidence
for the veracity of the findings in this study.

247 As for the other variants, the adjustments due to hypertension and the rs9644568 seem to 248 mask their statistical significance. This has several implications. First, rs9644568 is rarely reported 249 as a marker for LDL-C in the literature, but the statistical significance of rs9644568 stood out 250 prominently in the current study, thus implying that the SNP is unique among the Filipino 251 population. Second, hypertension might have masked the statistical significance of some of the 252 candidate genes in the metabolic syndrome context. This is unsurprising as some variants have been 253 previously associated with high blood pressure. To illustrate, ABCBI was reported to be associated 254 with hypertension through dietary salt transport and retention [32]. In a study among Han Chinese, 255 variants of ABCA1, rs2472510 and rs2515614, were associated with hypertension, with decreased 256 expression of ABCA1 linked with hypertension risk [33]. On the other hand, meta-analysis of 2799 257 cases and 6794 controls showed an association of CYP3A5 rs776746 with hypertension [34]. A later 258 study on a small sample of Han Chinese also reported a significant association of CYP3A5 rs776746 259 with the elevated risk of hypertension [35].

260 Several variants are mostly known genes whose roles in LDL-C metabolism are well 261 established [16-21]. The G allele of rs1532085 in LIPC with a protective effect for LDL-C levels in Chinese populations [36], is similar to the findings in this study. In a large GWAS study involving 262 263 >100,000 Caucasians, rs4299376 in ABCG8 was found to be one of the strongly associated genes with LDL-C [38]. The variant rs676210 in APOB has been identified as a susceptibility locus for 264 265 very low-density lipoprotein levels in the Women's Genome Health Study (WGHS) involving 17,296 women of European ancestry [38]. This association was further reported in the Chinese 266 Yugur population³⁹. A GWAS study of 11,685 showed a significant association of *CELSR2* rs660240 267 268 to LDL-C levels where the G allele is associated with risk and this was confirmed in a meta-analysis 269 of Below et al. (2016) [40,41].

270

However, some genes can be considered as attractive at best at this point. One intriguing

13

271 finding is the direct association of ABCB1 with LDL-C. There is scarce data on this association, as 272 most studies focused on its association with response to statins [42,43]. The variant ABCB1 273 rs1045642 is by itself associated with statin response [44]. The variant rs12279250 in NELL1, a growth factor of still uncertain significance, has been associated with increased triglyceride levels 274 275 [45,46], which may lead to a subsequent increase in LDL-C levels. Despite the study identifying 276 rs4149268 in ABCA1 as associated with LDL-C, most studies reported an association with HDL-277 C levels instead of LDL-C [47]. This may need to be verified, but it is noteworthy to investigate if 278 such an association remains among Filipinos. As for rs776746 in CYP3A5, there is little study on 279 the direct association with LDL-C levels. This could be due to the assumption that cytochrome P 280 proteins are mainly associated with drugs. In fact, most studies focused on response to cholesterol-281 lowering drugs [48,49]. As the present study focused on participants without drug intake, a possible 282 role for CYP3A5 on LDL-C level could be plausible. Similarly, there is minimal information on rs2686586. Even its association with the gene GOLIM4 is questionable, as no evidence of 283 284 regulation nor proximity (>50kb) is noted in the literature. Nonetheless, the fact that it is 285 significantly associated with LDL- C needs to be verified.

286 In this study, clinical variables that show a significant association with high LDL-C 287 phenotype are hypertension, BMI > 25 kg/m2, and ischemic heart disease (IHD). Several studies consistently show strong correlations between these comorbidities and LDL-C levels. The link 288 289 between LDL-C and hypertension was elucidated by the group of Laaksonen et al. (2008). They 290 reported that elevated serum levels of LDL-C increase the risk of hypertension in Finnish men, 291 which explained the strong association of dyslipidemia with incident hypertension [50]. Meanwhile, a previous study performed in the US population suggested a linear association of LDL-C 292 293 concentrations and BMI [51]. The association between high LDL-C levels and high IHD risk is 294 further substantiated by the study of Breuer (2005), focusing on improving cardiovascular disease 295 outcomes by lowering LDL-C levels [52]. Moreover, dyslipidemia and hypertension are known as 296 major risk factors for cardiovascular diseases; with these two comorbidities reported to be 297 frequently diagnosed in patients with ischemic heart disease [53].

14

| 298 | This study presents an opportunity to identify individuals at risk for developing high LDL-C |
|-----|---|
| 299 | levels by looking at their genetic profiles to complement clinical correlates. Estimated associations |
| 300 | between variant rs9644568 and hypertension were very high, but the confidence intervals around |
| 301 | them were too wide to rule out the possibility of substantial associations. Further studies with larger |
| 302 | sample sizes are required to validate the conclusions of this study. |
| | |

303 Conclusion

Genetic determinants largely influence the development of high LDL-C levels. This study
 found an association of variant rs9644568 in the intergenic region downstream of the *LPL* gene,
 with high LDL-C levels among Filipinos. Adding a genetic component may improve screening and
 assessment of patients at risk for developing high LDL-C levels.

307253; this version posted May 13, 2024. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/2024.05 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

References 309

310

[1] Mortensen MB, Dzaye, O., Bøtker, H.E., et al. Low-Density Lipoprotein Cholesterol Is 311 Predominantly Associated With Atherosclerotic Cardiovascular Disease Events in Patients 312 313 With Evidence of Coronary Atherosclerosis: The Western Denmark Heart Registry.

- 314 Circulation. 2023; 147(14): 1053-1063.
- 315 [2] Stanciulescu LA, Scafa-Udriste A & Dorobantu M. Exploring the Association between Low-
- 316 Density Lipoprotein Subfractions and Major Adverse Cardiovascular Outcomes-A 317 Comprehensive Review. Int J Mol Sci. 2023; 24(7): 6669.
- 318 [3] Abdullah SM, Defina LF, Leonard D, et al. Long-Term association of low-density lipoprotein
- 319 cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic
- 320 cardiovascular disease: results from the Cooper Center Longitudinal Study. Circulation. 2018; 321 138(21): 2315-25.
- 322 [4] Fernandez ML, Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate 323 coronary heart disease risk. Journal of the American College of Nutrition. 2008; 27: 1-5.
- 324 [5] Brown EE, Sturm AC, Cuchel M, et al. Genetic testing in dyslipidemia: A scientific statement 325 from the National Lipid Association. J Clin Lipidol. 2020; 14(4): 398-413.
- 326 [6] García-Giustiniani D, Stein R. Genetics of Dyslipidemia. Arg Bras Cardiol. 2016; 106(5): 434-438. 327
- 328 [7] Lipkin SM, Chao EC, Moreno V, et al. Genetic variation in 3-hydroxy-3methylglutaryl CoA 329 reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev 330 Res (Phila). 2010; 3(5): 597-603.
- 331 [8] Aulchenko YS, Ripatti S, Lindqvist I, et al. Loci influencing lipid levels and coronary heart 332 disease risk in 16 European population cohorts. Nat Genet. 2009; 41(1): 47-55.
- 333 [9] Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridket PM 334 Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004; 291(23): 335 2821-27.
- 336 [10] Ruaño G, Thompson PD, Kane, J.P., et al. Physiogenomic analysis of statin-treated

16

- patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein
 cholesterol? Pharmacog. 2010; 11(7): 959-7.
- Waterworth DM, Ricketts SL, Song K, et al. Genetic variants influencing circulating lipid
 levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol. 2010; 30(11),
 2264-76.
- Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid
 concentrations and risk of coronary artery disease. Nat Genet. 2008; 40(2): 161-9.
- 344 [13] Hsu LA, Teng MS, Wu S, et al. Common and Rare PCSK9 Variants Associated with Low-
- 345 Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian
 346 Randomization Study. International Journal of Molecular Sciences. 2022; 23(18): 10418.
- Guella I, Asselta R, Ardissino D, et al. Effects of PCSK9 genetic variants on plasma LDL
 cholesterol levels and risk of premature myocardial infarction in the Italian population. J.
 Lipid Res. 2010; 51: 342–3349.
- 350 [15] Elbers CC, Guo Y, Tragante V, et al. Gene-Centric Meta-Analysis of Lipid Traits in
 351 African, East Asian and Hispanic Populations. PLoS ONE. 2012; 7(12): e50198.
- Wu J, Wang X, Chen H, et al. Type 2 Diabetes Risk and Lipid Metabolism Related to the
 Pleiotropic Effects of an ABCB1 Variant: A Chinese Family-Based Cohort Study.
 Metabolites. 2022; 12: 875.
- 355 [17] Dijk W, Di Filippo M, Kooijman S, et al. Identification of a Gain-of-Function LIPC Variant
 356 as a Novel Cause of Familial Combined Hypocholesterolemia. Circulation. 2022; 146(10):
 357 724-739.
- Jacobo-Albavera L, Domínguez-Pérez M, Medina-Leyte DJ, et al. The Role of the ATPBinding Cassette A1 (ABCA1) in Human Disease. Int J Mol Sci. 2021; 22(4): 1593.
- [19] Benn M, Nordestgaard BG, Jensen JS, et al. Polymorphism in APOB Associated with
 Increased Low-Density Lipoprotein Levels in Both Genders in the General Population. The
 Journal of Clinical Endocrinology & Metabolism. 2005; 90(10): 5797–5803.
- 363 [20] Tada H, Okada H, Nomura A, et al. Beneficial effect of ezetimibe-atorvastatin combination
- therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis. 2020;

17

| 365 | 1 | 9(1): 3. |
|------------|-----------|---|
| 366 | [21] | Tan J, Che Y, Liu Y, et al. CELSR2 deficiency suppresses lipid accumulation in hepatocyte |
| 367 | b | y impairing the UPR and elevating ROS level. FASEB J. 2021; 35: e21908. |
| 368 | [22] | Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to |
| 369 | р | olygenic dyslipidemia. Nat Genet. 2009; 41(1):56-65. |
| 370 | [23] | Hoffmann TJ, Theusch E, Haldar T, Ranatunga DK, Jorgenson E, Medina MW, et al. A |
| 371 | la | arge electronic-health-record-based genomewide study of serum lipids. Nat Genet. 2018; |
| 372 | 5 | 0(3): 401. |
| 373 | [24] | Qin J, Tian J, Liu G, et al. Association between 1p13 polymorphisms and peripheral arterial |
| 374 | d | isease in a Chinese population with diabetes. J Diabetes Investig. 2018; 9(5):1189-95. |
| 375 | [25] | Kersten S. Physiological regulation of lipoprotein lipase. 2 0 2 Biochim Biophys Acta. |
| 376 377 | 1 | 841(7), 919-33 (2014). |
| 378 379 | [26] | Merkel M, Kako Y, Radner H, et al. Catalytically inactive lipoprotein lipase expression in |
| 380 | n | nuscle of transgenic mice increase very low density lipoprotein uptake: direct evidence that |
| 381 | li | poprotein lipase bridging occurs in vivo. Proc Natl Acad Sci USA. 1998; 95: 13841–13846. |
| 382 | [27] | Merkel M, Heeren J, Dudeck W, et al. Inactive lipoprotein lipase (LPL) alone increases |
| 383 | S | elective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also |
| 384 | ir | ncreases triglyceride hydrolysis and whole particle lipoprotein uptake. J Biol Chem. 2002; |
| 385 | 2 | 77: 7405–7411. |
| 386 387 | [28] | Mead JR, Ramji DP. The pivotal role of lipoprotein lipase in atherosclerosis. Cardiovasc Res. 2022; |
| 388 389 | 5 [29] | 5: 261–269. Mamputu JC, Desfaits AC, Renier G. Lipoprotein lipase enhances human monocyte |
| 390 | | dhesion to aortic endothelial cells. J Lipid Res. 1997; 38: 1722–1729. |
| | | |
| 391 | [30] | Pirahanchi Y, Anoruo M, Sharma S. Biochemistry, Lipoprotein Lipase. StatPearls. |
| 392 | Т | reasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC. |
| 393 | 2 | 022. |
| 394 | [31] | Su X, Peng DQ. New insights into ANGPLT3 in controlling lipoprotein metabolism and |

risk of cardiovascular diseases. Lipids Health Dis. 2018; 17(1): 12.

| 396 397 | [32] Bochud M, Bovet P, Burnier M, Eap CB. CYP3A5 and ABCB1 genes and hypertension. |
|------------|---|
| 398 399 | Pharmacogenomics. 2009; 10(3): 477-87 (2009). |
| 400 | [33] Ren Y, Tong E, Di C, et al. Association Between ABCA1 Gene Polymorphisms and the |
| 401 | Risk of Hypertension in the Chinese Han Population. Front Public Health. 2022; 10: 878610. |
| 402 | [34] Xi B, Wang C, Liu L, et al. Association of the CYP3A5 polymorphism (6986G>A) with |
| 403 | blood pressure and hypertension. Hypertens Res. 2011; 34(11): 1216-20. |
| 404 | [35] Li Z, Chen P, Zhou T, et al. Association between CYP3A5 genotypes with hypertension |
| 405 | in Chinese Han population: A case-control study. Clin Exp Hypertens. 2017; 39(3): 235-240. |
| 406 | [36] Khounphinith E, Yin RX, Qiu L, et al. Association of the LIPC rs1532085 SNP and serum |
| 407 | lipid traits in the Chinese Maonan and Han populations. Int J Clin Exp Pathol. 2018; 11(4), |
| 408 | :2038-2052. |
| 409 | [37] Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance |
| 410 | of 95 loci for blood lipids. Nature. 2010; 466(7307): 707-13. |
| 411 | [38] Chasman DI, Paré G, Mora S, et al. Forty-three loci associated with plasma lipoprotein |
| 412 | size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 2009; |
| 413 | 5(11): e1000730. |
| 414 | [39] Gu QL, Han Y, Lan YM, et al. Association between polymorphisms in the APOB gene |
| 415 | and hyperlipidemia in the Chinese Yugur population. Braz J Med Biol Res. 2017; 50(11): |
| 416 | e6613. |
| 417 | [40] Sandhu MS, Waterworth DM, Debenham SL, et al. LDL-cholesterol concentrations: a |
| 418 | genome-wide association study. Lancet. 2008; 371(9611): 483-91. |
| 419 | [41] Below JE, Parra EJ, Gamazon ER, et al. Meta-analysis of lipid-traits in Hispanics identifies |
| 420 | novel loci, population-specific effects, and tissue-specific enrichment of eQTLs. Sci Rep. 6, |
| 421 | 19429 (2016). |
| 422 | [42] Kadam P, Ashavaid TF, Ponde CK, et al. Genetic determinants of lipid-lowering response |
| 423 | to atorvastatin therapy in an Indian population. J Clin Pharm Ther. 2016; 41(3): 329-33. |
| 424 | [43] Shatnawi A, Kamran Z, Al-Share Q. Pharmacogenomics of lipid-lowering agents: the |
| 425 | impact on efficacy and safety. Per Med. 2023; 20(1): 65-86. |

- [44] Sun L, Wolska A, Amar M, et al. Approach to the Patient With a Suboptimal Statin
 Response: Causes and Algorithm for Clinical Management. J Clin Endocrinol Metab. 2023;
 108(9): 2424-2434.
- 429 [45] Cheng X, Shi J, Jia Z, et al. NELL-1 in Genome-Wide Association Studies across Human
 430 Diseases. Am J Pathol. 2022; 192(3): 395-405.
- 431 [46] Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, et al. Genome-wide association
 432 analyses suggest NELL1 influences adverse metabolic response to HCTZ in African
 433 Americans. Pharmacogenomics J. 2014; 14(1): 35-40.
- 434 [47] Paththinige CS, Sirisena ND, Dissanayake V. Genetic determinants of inherited
 435 susceptibility to hypercholesterolemia a comprehensive literature review. Lipids Health Dis.
 436 2017; 16(1): 103.
- 437 [48] Jiang XY, Zhang Q, Chen P, et al. CYP7A1 polymorphism influences the LDL cholesterol438 lowering response to atorvastatin. J Clin Pharm Ther. 2012; 37(6): 719-23.
- [49] Lim MYC, Tee JR, Yau WP, et al. A meta-analysis of the pooled impact of CYP7A1 single
 nucleotide polymorphisms on serum lipid responses to statins. Front Genet. 2023; 14:
 1199549.
- 442 [50] Laaksonen DE, Niskanen L, Nyyssönen K, et al. Dyslipidaemia as a predictor of
 443 hypertension in middle-aged men. Eur Heart J. 2008; 29(20): 2561-8.
- 444 [51] McLaughlin T, Allison G, Abbasi F, et al. Prevalence of insulin resistance and associated
 445 cardiovascular disease risk factors among normal weight, overweight, and obese individuals.
 446 Metabolism. 2004; 53(4): 495-9.
- 447 [52] Breuer HW. Low Density Lipoprotein Cholesterol and Coronary Heart Disease Lower is
 448 Better. European Cardiology. 2005; 1(1): 1-6.
- 449 [53] Singh BM, Mehta JL. Interactions Between the Renin-Angiotensin System and
 450 Dyslipidemia: Relevance in the Therapy of Hypertension and Coronary Heart Disease. Arch
 451 Intern Med. 2003; 163(11): 1296–1304.
- 452
- 453

454 455

Acknowledgements

456 The authors would like to express their sincere gratitude to the administrative staff and 457 researchers of the Microarray Laboratory of the Institute of Human Genetics, National Institutes 458 of Health-University of the Philippines Manila, the Philippine Genome Center, and the clinical 459 fellows of the Department of Medicine for actively being involved in the project. We are 460 extending our gratitude to our sponsor, the Philippine Council for Health Research and 461 Development of the Department of Science and Technology (PCHRD-DOST)

Author Contributions 462

463 EMCutiongco-De La Paz, conceptualized the study and designed the methodology, acquired 464 funding and led the project administration and supervision, conducted the research and 465 investigation process, performed the data curation and analysis, interpreted the data, wrote the 466 original draft, reviewed and edited the manuscript for intellectual content; JBNevado 467 conceptualized the study and designed the methodology, acquired funding and led the project 468 administration and supervision, conducted the research and investigation process, performed the 469 data curation and analysis, interpreted the data, wrote the original draft, reviewed and edited the 470 manuscript for intellectual content; LEGSantos, conceptualized the study and designed the 471 methodology, conducted the research and investigation process, interpreted the data; 472 AYCLAman, acquired funding and led the project administration and supervision, conducted the 473 research and investigation process, performed the data curation and analysis, interpreted the data, 474 wrote the original draft; JDAMagno, conceptualized the study and designed the methodology, conducted the research and investigation process, interpreted the data; PMMReganit, 475 476 conceptualized the study and designed the methodology, conducted the research and investigation process, interpreted the data; RHPTiongco, conceptualized the study and designed the 477 478 methodology, conducted the research and investigation process, interpreted the data; **DIDOna**, 479 conceptualized the study and designed the methodology, conducted the research and investigation 480 process, interpreted the data; FERPunzalan, conceptualized the study and designed the 481 methodology, conducted the research and investigation process, interpreted the data; EJBLlanes,

482 conceptualized the study and designed the methodology, conducted the research and investigation 483 process, interpreted the data; **JAMAherrera**, conducted the research and investigation process, 484 interpreted the data; CMOFernandez, performed the data curation and analysis, interpreted the 485 data, reviewed and edited the manuscript for intellectual content; LLAbrahan, conducted the 486 research and investigation process, interpreted the data; CFAgustin, conducted the research and 487 investigation process, interpreted the data; AJPBejarin, conducted the research and investigation 488 process, performed the data curation and analysis, interpreted the data, wrote the original draft; 489 **RGSy**, conceptualized the study and designed the methodology, acquired funding and led the 490 project administration and supervision, conducted the research and investigation process, 491 interpreted the data, reviewed and edited the manuscript for intellectual content

492 **Data Availability Statement**

- 493 The datasets used and/or analyzed during the current study are available from the corresponding
- 494 author on reasonable request.

495 **Competing Interests**

496 The authors declare no competing interests.

497 **Funding Source**

- 499 The present study was sponsored by a grant-in-aid from the PCHRD-DOST
- 500

498